CanSino Biologics Inc.
BiotechTianjin, China, China · Est. 2011
CanSino Biologics is a Chinese biopharmaceutical company specializing in the development and commercialization of vaccines, including the COVID-19 vaccine Ad5-nCoV.
10
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
6
Indications↗
Distinct diseases across all programs
36
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
10 drugs in development
Approved1
Phase 32
Phase 22
Phase 17
Preclinical1
By Therapeutic Area
top 2
Infectious Disease
982%
Immunology
19%
R&D Momentum
45/100
Pipeline Velocity
15/100
Trial Completion Rate
86/100
Pipeline Concentration
69/100
Pipeline Freshness
80/100
Strategic Signals
- ↗Active in Immunology but thin pipeline — potential licensing opportunity
Activity
Key Events
Dec 19, 2025TrialClinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
Nov 14, 2025TrialA Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
Nov 13, 2025TrialA Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years
Mar 23, 2025TrialInter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine
Dec 20, 2024TrialA Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)
Dec 19, 2024TrialA Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers
Dec 14, 2024TrialA Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds
Nov 15, 2024TrialClinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
4 more events
Jun 12, 2024TrialClinical Study of the Safety of Menhycia® in 3-Month-Old Infants
Mar 20, 2024TrialA Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
Mar 20, 2024TrialA Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over
Mar 1, 2024TrialA Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
VaccinesImmunologyInfectious Diseases
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology
Infectious Disease
Immunology
Infectious Disease
Diphtheria
DTaP-IPV-HibPhase 3
DTcPPhase 3
Influenza
DTcP-Hib-MCV4Phase 1
MCV4Phase 1
Poliomyelitis
VLP-PolioPhase 1
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)